哪里想瘦打哪里！FDA批准Kythera麻醉药物上市在即

你才双下巴，你全家都双下巴！；也爱美之心人皆有之。如果说赘肉是每一个想保有令人难忘长相的“妹纸”或“汉纸”的厉，那么一个喜感十足的双下巴算得是这些人的生死罪人了。每一分钟，各种类型都有人为自己的一张大饼脸而不能忍受烦恼，虽然保有一个肉感十足的双下巴扯上去是挺有肉感的，但是还是有很多人的心理素质使其不能太重一个双下巴之重。您可千万别哭，这甚至已经成百上千一个浩大的市场。根据英国皮肤上放射治疗基金会的调查学术研究显示，68%的英国人对自己的双下巴声称了“厌倦”之情。而有鉴于此，近来Kythera的公司向FDA草拟了其专供消灭双下巴的按摩注射型式本品ATX-101。这种本品进行时了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，算得是定点减肥。绝不以为这种近乎任性的本品只是一个哭话，在FDA下属的皮肤上和眼科本品专员会的无记名投票中会，科学家可是以17：0的超高高票一致附和其港交所。显然是因为这些科学家中会也有很多倍受双下巴之苦吧。FDA也将计划于今年的5年末13日以后对其跟进最后要求。如果一切顺利的话，Kythera的公司计划于今年下半年将该产品港交所，系统性人士届时这一本品的年销售额将超过3亿美元之多。随着按摩本品市场的日益增大，Kythera的公司算得是下了一步好棋。的公司于今年以8400万美元的价格从其前伙伴波鸿主导权会收回了这种本品的全部自由权。而Kythera的公司也想用意为后所在按摩本品市场中会攻城拔寨。就在上个年末，Kythera的公司和Actelion的公司定下价值2700万美元的合作条款，共同整合一种最终过的抗上皮细胞本品，而这种本品被指借助于有可能整合借助于一种病人皮肤上病的本品。详细法文报导：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.